The antigen processing requirements for urushiol, the immunogen of poison ivy (Toxicodendron radicans), were tested by presentation of urushiol to cultured human urushiol-responsive T cells. Urushiol was added to antigen-presenting cells (APC) either before or after fixation with paraformaldehyde. Three distinct routes of antigen processing were detected. CD8+ and CD4+ T cells, which were dependent upon processing, proliferated if urushiol was added to APC before fixation, but did not proliferate when urushiol was added to APC after fixation. Processing of urushiol for presentation to CD8+ T cells was inhibited by azide, monensin, and brefeldin A. This suggests that urushiol was processed by the endogenous pathway. In contrast, presentation of urushiol to CD4+ T cells was inhibited by monensin but not by brefeldin A. This was compatible with antigen processing by the endosomal (exogenous) pathway. Finally, certain CD8+ T cells recognized urushiol in the absence of processing. These cells proliferated in response to APC incubated with urushiol after fixation. Classification of contact allergens by antigen processing pathway may predict the relative roles of CD4+ and CD8+ cells in the immunopathogenesis of allergic contact dermatitis. (J. Clin. Invest. 1994. 93
Introduction
Antigen processing can proceed by distinct pathways. These pathways may determine the relative contributions of CD4+ and CD8+ T cells in an immune response as well as the immunopathology induced by an antigen. Haptens conjugate proteins by a variety ofchemical reactions and have a broad range ofphysical properties. It is likely that this diversity in the chemical properties of haptens is reflected in a diversity of antigen processing and presentation pathways.
Urushiol is the active immunogen ofpoison ivy and poison oak ( 1, 2) . It is a lipid-soluble molecule composed ofa catechol nucleus substituted on C4 with a C1 5 (poison ivy) or Cl 7 (poison oak) hydrophobic tail (3, 4) . Covalent binding ofurushiol to proteins requires oxidation to a quinone intermediate (5) which is susceptible to nucleophilic substitution by amino Receivedfor publication 30 July 1993 and in revisedform 12 January 1994. groups or sulfhydryl groups. An alternative mechanism ofactivation involving oxidation to free radical intermediates has also been proposed (6) .
Antigen processing proceeds by different pathways depending upon whether the antigen is an extrinsic protein or an endogenously synthesized protein (7) (8) (9) . Extrinsic antigens are phagocytosed or endocytosed and degraded into peptides within the endosome/lysosome compartment. Processed antigenic peptides associate with class II MHC molecules within the endosome/lysosome compartment for eventual presentation to CD4+ T cells. Newly synthesized MHC class II molecules are prevented from binding peptides before transport to the endosomal compartment by association with the invariant chain ( 10) . Inhibitors that interfere with endosome-dependent protein processing include chloroquine ( 1) , monensin ( 12) , leupeptin ( 13) , and ammonium chloride ( 11 ) . Peptides isolated from murine MHC class II molecules include secretory and membrane proteins with access to endosomal compartments ( 14) .
In contrast, proteins synthesized endogenously are degraded into peptides and transported into the endoplasmic reticulum where they associate with class I MHC molecules for eventual presentation to CD8+ T cells. Degradation of cytoplasmic proteins into peptides of approximately nine amino acids in length is believed to be a function of the proteasome complex ( 15) , a 26S multisubunit complex with protease activity. The genes for several subunits ofthis complex are linked to the MHC class II region ( 16, 17) . Transport of cytoplasmic peptides into the endoplasmic reticulum is dependent upon transporter proteins which bind ATP and are coded by the Tap-1 and Tap-2 genes, which also map within the MHC class II region (18) (19) (20) (21) . T2 cells are defective in this ability to transport peptides and are unable to process endogenous peptides for presentation on MHC class 1 (22, 23) . Class I MHC molecules associate with peptides within the endoplasmic reticulum and are transported to the golgi complex for presentation on the cell surface (24) . In addition to its effects on endosomal antigen processing, monensin disrupts the golgi complex, inhibiting transport to the plasma membrane (25). Brefeldin A interferes with transport ofproteins from the endoplasmic reticulum to the golgi complex (26) , thereby inhibiting presentation of proteins dependent upon the endogenous presentation pathway (27) .
Since MHC class II molecules present to CD4+ cells and class I MHC molecules present to CD8+ cells, extrinsic antigens are recognized by CD4+ cells, and endogenous peptides are recognized by CD8+ cells. This correlation is not absolute, as under certain circumstances endogenous antigens may be presented by MHC class II molecules (28) .
A high proportion of CD8+ human urushiol-specific T cell clones are CD8+ (29) (30) (31) , and class I MHC restriction was demonstrated for one such urushiol-specific clone (29) . This suggests that processing of urushiol-conjugated proteins proceeds by the endogenous pathway. There is also murine evi-dence for CD8+ T cell recognition of such haptens as dinitrofluorobenzene (DNFB)' (32) . Since urushiol is an exogenous substance, we hypothesized that the lipid-soluble molecule enters the cell, conjugates intracellular proteins, and is presented by MHC class I molecules to CD8+ cells.
The goal ofthis study was to determine the antigen processing requirements for urushiol. Processing requirements were studied by the addition of urushiol to antigen-presenting cells (APC) either before or after fixation with paraformaldehyde. Antigen processing pathways were further delineated by the use of inhibitors.
Methods
Urushiol. Purified urushiol was the generous gift of Dr. H. Baer of the Bureau of Biologics, Food and Drug Administration (Bethesda, MD). Analysis of the purified urushiol by gas chromatography showed no saturated side chains and a minimum of 95% catechol (Dr. Alfred V. Del Grosso, personal communication). The material was 85.1% C15 triene, 10.2% combination mono and diene, and 4.7% C17 triene. Urushiol was used in cell culture at a concentration of 1.0 ,g/ml (31 Isolation of CD4+ and CD8+ T cells by negative selection with magnetic particles. After 2 wk ofculture, cultured T cells were purified by sheep erythrocyte rosetting as described previously (33) . CD4+ and CD8+ T cells were then purified by negative selection with magnetic particles. T cells (10 X 106 cells/ 15-ml tube) were incubated with 0.75 ml of a 1:250 dilution of appropriate ascites (anti-CD4, l9Thy5D7; anti-CD8, 7Pt3F9) on ice for 30 min and washed three times. Magnetic particles conjugated with goat anti-mouse IgG (Advanced Magnetics, Inc., Cambridge, MA) were washed four times and resuspended in suspension culture MEM (S-MEM)/2.5% newborn calf serum (NBCS) at 5 x 10 particles/ml. The magnetic particles ( 1.0 ml) were then added to the T cell pellet, which was resuspended and incubated on ice for 30 min. Magnetic particles and associated cells were brought up to a total volume of 7.0 ml, and magnetic particles were removed by two magnetic separations (7 min each). Negatively selected cells were then washed twice and resuspended in AIM V media. Both CD4+ and CD8+ cells were frequently selected from the same T cell line and are designated with the same experiment number. Paraformaldehydefixation ofAPC. After preincubations as above, APC were fixed in 0.12% paraformaldehyde by a modification of published procedures (12, 34) . Freshly prepared paraformaldehyde was added to APC ( 1.0 ml to a pellet of 1.5 X 106 cells in a 5-ml tube) for a 5-min incubation at 250C. Incubation was stopped by the addition of 4.0 ml of glycine buffer (0.15 M, pH 7.4), followed by three washes with S-MEM containing 2.5% heat-inactivated NBCS. T cell proliferation assays. Cultured CD4+ and CD8+ T cells were washed twice and incubated at 370C for 2 h in S-MEM/2.5% NBCS before a final wash, after which they were resuspended at 2.5 x 105 cells/ml in AIM V medium. T cells (0.1 ml) were added to APC (0.1 ml) in 96-well U-bottom plates for a total volume of 0.2 ml/well. Replicates of six wells were used for each treatment group. When indicated, anti-CD28 ascites (4B10, obtained from Chikao Morimoto, Dana-Farber Cancer Institute, Boston, MA) were added to the wells at a final dilution of 1:500 (35) . Wells were pulsed with [3H]thymidine 
Results
Generation and phenotyping of human urushiol-and tetanus toxoid-responsive T cell lines. Using the procedure described above, short-term human T cell lines were generated in response to tetanus toxoid and urushiol. 2 wk after initiation of cultures, the T cells were purified by sheep erythrocyte rosetting and phenotyped for expression of CD3, CD4, and CD8. Tetanus toxoid-responsive lines were uniformly CD3+ CD4+ CD8-, and urushiol-responsive lines were predominantly CD3+ CD8+ (Table I) . This was compatible with our previously published reports on urushiol-specific T cell lines and clones from three individuals (29) (30) (31) . Several urushiol-specific lines exhibited a significant proportion of double-positive CD4+ CD8+ cells. This has been confirmed with two-color immunofluorescence and reported previously for a urushiolspecific T cell clone (29) . Antigen-specific lines from a fourth individual demonstrated similar findings for both urushiol (CD3+ 98%/CD4+ 35%/CD8+ 81%) and tetanus toxoid (CD3+ 93%/CD4+ 93%/CD8+ 3%). Table I demonstrates the predominance of CD8+ urushiol-specific T cells for these nine urushiol-specific lines. Since CD4+ and CD8+ cells were purified before use, it was not necessary to determine the phenotype of the unseparated cells, and subsequent T cell lines were not phenotyped.
The predominance of CD8+ urushiol-specific T cell lines was not an artifact of the culture system since CD4+ CD8-T cell lines specific for tetanus toxoid were generated from the same donor using the same procedure (Table I) . Urushiol specificity was demonstrated by proliferation in response to urushiol but not tetanus toxoid (Table II) . T cell lines from the same donor, generated by in vitro stimulation with tetanus toxoid, proliferated in response to tetanus toxoid but not urushiol. After purification by sheep red blood cell rosetting, T cell lines demonstrated levels of staining below background (1%) with markers for macrophages (MO1 ) and B cells (B 1). Staining for the y/6 T cell receptor (T cell receptor-5 1) was also negative. Urushiol T cell lines depleted of CD4+ cells with magnetic particles contained > 95% CD8+ cells and < 3% CD4+ cells. The CD8+-depleted urushiol-responsive cell lines contained < 9% CD8+ cells.
Antigen processing requirements for urushiol: (antigen pulse/fix) vs (fix/antigen pulse). The requirement for processing of urushiol by APC was studied by replicating classic (fix/ pulse) vs (pulse/fix) experiments (36, 37) . This required the use of paraformaldehyde-fixed APC. Anti-CD28 has been shown to reconstitute the response of human CD4+ T cells to tetanus toxoid presented by fixed APC (38) . We have found that anti-CD28 also allows fixed PBMC to present urushiol to human urushiol-specific CD8+ T cells (39) . For this reason, anti-CD28 (1:500 ascites) was added to cultures in which fixed erythrocyte rosette negative fraction [(E-) cells] functioned as APC.
APC were incubated with urushiol (1 tg/ml) for 1 h at 37°C either before or after fixation with paraformaldehyde. Control fixed APC were not exposed to urushiol. Fixed APC were then added to purified CD4+ or CD8+ urushiol-responsive cultured T cells, and T cell proliferation was measured by
[3H ]thymidine uptake. Experiments were performed with both autologous (E-) and EBV8 17 cells as APC. When fixed autologous (E-) cells were used as APC, anti-CD28 ascites were added at 1:500 dilution. Autologous EBV transformed B cells (EBV8 17) were not dependent on anti-CD28 for antigen presentation as EBV transformed B cells express a high constitutive level of B7/BB1 (38) .
The antigen processing requirements for presentation to CD8+ T cells exhibited heterogeneity (Figs. 1 and 2 ). Certain CD8+ T cells proliferated optimally if the urushiol was presented by APC incubated with urushiol before fixation (Fig. 1 , URUSHIOL/FIX). APC that were fixed before incubation with urushiol (Fig. 1 , FIX/URUSHIOL) were less effective at presenting urushiol to these T cells. These CD8+ T cells required processing of the urushiol by a viable APC. Fixation with 0.12% paraformaldehyde for 5 min was found to reduce
[3H ]leucine uptake of APC to the level of uptake in the presence of 1% azide (Table III) , confirming the lack ofviability of the fixed cells. Processing dependence of CD8+ cells was demonstrated both with autologous (E-) and EBV8 17 cells as APC.
Processing-independent CD8+ T cells were also detected. These CD8+ cells were able to recognize APC incubated with urushiol after fixation (Fig. 2, FIX (Fig. 3) . APC that had been incubated with urushiol before fixation (Fig. 3 , URUSHIOL/FIX) were able to induce proliferation. However, fixation of APC before urushiol incubation (Fig. 3 , FIX/URUSHIOL) abrogated the ability of the CD4+ cells to respond. Similar data were obtained whether (E-) or EBV8 17 cells were used as APC. CD4+ cells purified from line E1 3 1B24 were tested against both (E-) and EBV817 cells as APC on the same day with similar results. CD8+ cells purified from this same line were also tested against (E-) cells as APC (Fig. 1) . trast, none of these inhibitors altered presentation of urushiol to processing-independent CD8+ T cell lines (Table VI) . This serves as a negative control for the inhibitors since processing was not required for presentation to these T cells.
Processing ofurushiolforpresentation to CD4+ Tcells was sensitive to monensin but not brefeldin A. Presentation of urushiol by either (E-) or EBV8 17 cells to cultured CD4+ T cells was inhibited by monensin but not brefeldin A (Table VII) . The lack of inhibition by brefeldin A along with the inhibition by monensin was consistent with the processing of urushiol by the endosomal pathway for presentation to CD4+ cells by class II MHC.
Processing oftetanus toxoidfor presentation to CD4+ cells was inhibited by monensin but not by brefeldin A. Tetanus toxoid-specific T cell lines derived from the same donor were used 48 (7) 51 (7) 168 (86) R31-3B2-5
49 (4) 45 (4) 125 (8) * Proliferation in dpm x 10-2. Numbers in parentheses represent SEM.
as a positive control for the antigen processing assay. APC were incubated with inhibitors for 1 h, then incubated with tetanus toxoid for 1 h and fixed as above.
Monensin was able to inhibit processing of tetanus toxoid. However, brefeldin A was not inhibitory under these conditions (Table VIII) . These data further confirm the specificity of brefeldin A for the endogenous pathway of antigen processing under these conditions.
Azide-inhibited processing of urushiol for presentation to CD8+ cells but not CD4+ cells. APC were incubated with azide for 1 h before addition of urushiol for a second 1-h incubation as above. APC were then fixed, washed, and tested for their ability to present urushiol to both CD4+ and CD8+ urushiolresponsive T cells.
Azide treatment under these conditions inhibited the ability to process urushiol for presentation to CD8+ cells but not CD4+ cells (Table IX) . This suggests that processing of urushiol for presentation to CD8+ cells was dependent upon oxidative cell metabolism.
Discussion
Three alternative routes were defined by which urushiol can be presented to human T cells. CD8+ T cells recognized urushiol processed by the endogenous antigen processing pathway. (2) 144 (14) 129 (16) APC were incubated with urushiol for 1 h either before (Urushiol/fix) or after (Fix/urushiol) fixation with paraformaldehyde. Control APC were fixed without exposure to urushiol (Fix). The effects of inhibitors on antigen processing were tested by incubating APC with inhibitors as indicated for 1 h, urushiol was then added for a 1-h incubation, and the APC were fixed. Cultured T cells were added to the urushiol-treated APC, and proliferation was determined by [3Hjthymidine uptake after a 24-h incubation. Groups consisted of replicates of six wells. SEM shown in parentheses. * Proliferation in dpm X 10-2.
CD4+ T cells recognized urushiol processed by the exogenous, endosome-dependent antigen processing pathway. Urushiol conjugated to extracellular proteins ("extracellular hapten") should be processed in this manner. Finally, certain CD8+ cells recognized urushiol without processing. This implies recognition of urushiol directly conjugated to either the MHC class I molecule or a peptide in the antigen-binding groove. These processing alternatives were supported by (fix/antigen) vs (antigen/fix) experiments and inhibitor studies. Lack of inhibition of presentation to processing-independent T cells by either inhibitor provided a negative control for the processing assay. Inhibition of processing of tetanus toxoid by monensin but not brefeldin A demonstrated the specificity ofbrefeldin A for the exogenous pathway under these conditions. Recognition of urushiol by certain CD8+ cells in the ab- Fix 143* (7) 22 (7) 28 (7) Urushiol/fix 575 (24) 133 (17) Monensin is a sodium ionophore that interferes with both endosomal function ( 12) and transport of proteins from the golgi complex (25) by collapsing proton gradients (41, 42) . The ability of monensin to interfere with golgi complex function has been overlooked in the immunology literature. This interference with transport from the golgi complex can explain the ability of monensin to inhibit presentation to CD8+ cells. Monensin inhibits endosomal/lysosomal antigen processing by preventing acidification of lysosomes. Chloroquine also inhibits endosomal antigen processing by raising intralysosomal pH (43) .
Brefeldin A inhibition ofprocessing indicates that transport from the endoplasmic reticulum was required for presentation to CD8+ cells (26, 27) . When added for a sufficient period of time, brefeldin A can also inhibit presentation of exogenous antigens on MHC class II on the basis ofinhibition oftransport of newly synthesized MHC class II molecules (44) . However, when brefeldin A was present for a total of2 h, the presentation of tetanus toxoid or urushiol to CD4+ T cells was not inhibited, indicating a selectivity for the exogenous pathway of antigen processing under these conditions. The lack of inhibition of processing of tetanus toxoid is an important control for the specificity ofbrefeldin A action, since tetanus toxoid is an exogenous protein which should be processed by the exogenous pathway. An additional negative control was provided by the inability of either monensin or brefeldin A to inhibit presentation ofurushiol to the processing-independent CD8+ urushiolspecific lines. The predominance of CD8+ urushiol-specific T cell lines and clones in the urushiol response (29) (30) (31) (45, 46) . Other allergens such as DNFB evoke a combined CD4+ and CD8+ response (32) . Urushiol, in contrast, evokes a predominantly CD8+ response (29) (30) (31) . It is proposed that nickel and cobalt are extracellular haptens that associate with proteins extracellularly. These extracellular proteins are subsequently internalized and processed by the exogenous pathway for presentation to CD4+ cells. Urushiol may function as an "intracellular hapten" and may conjugate cytoplasmic proteins for subsequently degradation and presentation by the endogenous pathway to CD8+ cells. Small chemically reactive lipid-soluble molecules such as DNFB and urushiol should be both capable of conjugating extracellular proteins and penetrating cell membranes to conjugate intracellular proteins. As predicted by this theory, DNFB evokes a mixed CD4+ and CD8+ response (32) .
There is additional evidence that T cells recognize haptens on processed peptides. Trinitrophenol (TNP)-specific murine T cell clones recognize TNP conjugated to peptides (47). The recognition of the TNP peptides is dependent upon the position of TNP within the peptide rather than the peptide sequence (48) . Provided the ability to bind MHC class I (H2Kb) was retained and the TNP was located on the fourth amino acid residue, T cell clones recognized a variety of peptides with varying sequence. Recognition of TNP could be blocked by anti-TNP antibody, suggesting TNP was oriented outward in the MHC peptide groove. Recognition of TNP peptide by murine T cell clones has been mapped to preferential use of specific V and J junctional regions (49) . Nickel also binds to peptides bound to MHC antigens, possibly through histidine residues. Nickel can bind to preprocessed peptides on fixed APC (50) , indicating that processing is not necessary if the hapten binds to preprocessed peptide.
This proposed classification of haptens into intracellular and extracellular haptens may have relevance to conditions other than allergic contact dermatitis. Certain drugs such as sulfonamides (51) and phenytoin (52) are metabolized into chemically reactive forms intracellularly. It is predicted that these drugs would also function as intracellular haptens and the T cell response to these drugs in patients with drug eruptions would be mediated by CD8+ cells. This is supported by the isolation of CD8+ T cells specific for sulfonamide (53) and penicillin (54) from bullous drug eruptions.
Three mechanisms for processing and presentation of urushiol were delineated. Urushiol could act as an intracellular hapten and be processed by the endogenous pathway for presentation to CD8+ T cells. Presentation to CD4+ T cells followed processing by the exogenous pathway (extracellular hapten). Finally, certain CD8+ T cell lines were found to recognize urushiol without processing, presumably after direct conjugation to either MHC class I molecules or peptides in the antigenpresenting groove. This classification of haptens by presentation pathway may explain the differential response of CD4+ and CD8+ T cells to various haptens and may provide a framework for understanding allergic contact dermatitis.
